Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy ...

These data were presented today during a late-breaking session at the American Heart Association (AHA) Scientific Sessions and published simultaneously in The New England Journal of Medicine (NEJM) in ...

Stifel: Analyst Paul Matteis adjusts the target price from $494 to $445, maintaining a hold rating. This mixed bag of ratings illustrates the cautious optimism surrounding Vertex Pharmaceuticals, as ...

Fresh leaks on Google's Vertex AI platform point to an imminent launch for Gemini 3 Pro and Nano Banana 2, as the company ...

Google Cloud has rolled out a series of updates to its Vertex AI Agent Builder in the hope that developers continue to build, test and deploy AI agents on its platform, with an emphasis on faster ...

It's been a sad week for Vertex, Inc. ( NASDAQ:VERX ), who've watched their investment drop 14% to US$20.08 in the ...

The round, completed in under a week, comes amid heightened interest in deterministic conversational AI and precedes a larger raise now in advanced stages. AUI relies on a fusion of the transformer ...

Both companies are leaders in their niche with excellent growth prospects. They could deliver market-beating returns through ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...